ArticleScience China. Life sciences2025
SELENBP1 protects against kidney fibrosis in chronic kidney disease as a methanethiol oxidase.
Article in Science China. Life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a global health concern characterized by a gradual decline in kidney function. Despite advancements in screening and diagnostic markers for CKD, there remains an urgent need to identify patients in the early stages. In this study, we analyzed human blood and kidney samples and found that selenium-binding protein 1 (SELENBP1) is downregulated in CKD patients, with its levels positively correlating with the estimated glomerular filtration rate (eGFR). To further explore the role of SELENBP1 in renal fibrosis, we performed high-throughput proteomic analysis using mouse plasma from adenine diet-induced mice with kidney failure. The results showed that SELENBP1 was significantly downregulated in both plasma and kidney samples from mice at early and late CKD stages in both adenine diet-induced and unilateral ureter obstruction (UUO) mouse models, aligning with findings from human samples. In vitro experiments utilizing human renal proximal tubular HK-2 cells revealed that SELENBP1 knockdown promoted fibrosis, whereas its overexpression inhibited fibrotic processes. Moreover, nuclear magnetic resonance (NMR) spectroscopy indicated that plasma dimethyl sulfone (DMSO
Indexed as
Identifiers
40864235What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.